Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

被引:32
作者
Takamori, Shinkichi [1 ]
Toyokawa, Gouji [1 ]
Okamoto, Isamu [2 ]
Takada, Kazuki [1 ,3 ]
Kozuma, Yuka [1 ]
Matsubara, Taichi [1 ]
Haratake, Naoki [1 ]
Akamine, Takaki [1 ]
Katsura, Masakazu [1 ]
Mukae, Nobutaka [4 ]
Shoji, Fumihiro [1 ]
Okamoto, Tatsuro [1 ]
Oda, Yoshinao [3 ]
Iwaki, Toru [5 ]
Iihara, Koji [4 ]
Nakanishi, Yoichi [2 ]
Maehara, Yoshihiko [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 8128582, Japan
[2] Kyushu Univ, Chest Grad Sch Med Sci, Res Inst Dis, Fukuoka, Japan
[3] Kyushu Univ, Dept Anat Pathol, Grad Sch Med Sci, Fukuoka, Japan
[4] Kyushu Univ, Dept Neurosurg, Grad Sch Med Sci, Fukuoka, Japan
[5] Kyushu Univ, Dept Neuropathol, Neurol Inst, Grad Sch Med Sci, Fukuoka, Japan
关键词
Programmed cell death-ligand 1; immunotherapy; non-small cell lung cancer; BRAIN METASTASES; PREDICTIVE BIOMARKERS; EXPRESSION; PD-L1; PEMBROLIZUMAB; ALECTINIB; NIVOLUMAB; ERLOTINIB; CHEMOTHERAPY; CRIZOTINIB;
D O I
10.21873/anticanres.11813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To investigate the discordance in the programmed cell death-ligand 1 (PD-L1) expression between primary and metastatic tumors and analyze the association between the discordance and the clinical factors in non-small cell lung cancer (NSCLC) patients. Patients and Methods: Twenty-one NSCLC patients who underwent surgery or biopsy for paired primary and metastatic lesions at our Institution from 2005 to 2016 were analyzed. Lesions with the PD-L1 expression being >= 5% were considered PD-L1-positive. Results: The metastatic sites included the brain (n=16), adrenal gland (n=3), spleen (n=1) and jejunum (n=1). Negative conversion of the primary PD-L1-positive NSCLC and positive conversion of the primary PD-L1-negative NSCLC were observed in 3 (14%) and 2 (10%) cases, respectively. Radiotherapy for the metastatic brain lesion before its resection showed a significant relationship with the positive conversion of the primary PD-L1-negative NSCLC (p=0.048). Conclusion: Radiotherapy-derived effects may contribute to the positive conversion of the primary PD-L1-negative NSCLC.
引用
收藏
页码:4223 / 4228
页数:6
相关论文
共 50 条
  • [41] The radiomic biomarker in non-small cell lung cancer: 18F-FDG PET/CT characterisation of programmed death-ligand 1 status
    Wang, Y. B.
    He, X.
    Song, X.
    Li, M.
    Zhu, D.
    Zhang, F.
    Chen, Q.
    Lu, Y.
    Wang, Y.
    [J]. CLINICAL RADIOLOGY, 2023, 78 (10) : E732 - E740
  • [42] Programmed death ligand 1 expression and CD8+ tumor-infiltrating lymphocyte density differences between paired primary and brain metastatic lesions in non-small cell lung cancer
    Zhou, Jie
    Gong, Zhihua
    Jia, Qingzhu
    Wu, Yan
    Yang, Zhen-Zhou
    Zhu, Bo
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 498 (04) : 751 - 757
  • [43] Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?
    Gainor, Justin F.
    [J]. CANCER CYTOPATHOLOGY, 2017, 125 (08) : 591 - 593
  • [44] Immunohistochemical Expression of Programmed Death-Ligand 1 in Diabetic Patients vs Non-Diabetics with Non-Small Cell Lung Cancer
    Zaleski, M.
    Sharzehi, S.
    Voland, R.
    Varlotto, J.
    Rassaei, N.
    Liu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S949 - S949
  • [45] Programmed Death-ligand 1 Expression Analysis for Non-small Cell Lung Cancer in Tissues Sampled Using Different Methods
    Urer, Halide Nur
    Gunluoglu, Mehmet Zeki
    Cansever, Levent
    Bedirhan, Mehmet Ali
    [J]. HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, 2020, 58 (02): : 135 - 141
  • [46] Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer
    Chen, Bolin
    Yang, Min
    Li, Kang
    Li, Jia
    Xu, Li
    Xu, Fang
    Xu, Yan
    Ren, Dandan
    Zhang, Jiao
    Liu, Liyu
    [J]. ONCOLOGY LETTERS, 2021, 22 (01)
  • [47] The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis
    Ma, Guangzhi
    Deng, Yunfu
    Jiang, Hai
    Li, Wen
    Wu, Qiang
    Zhou, Qinghua
    [J]. CLINICA CHIMICA ACTA, 2018, 482 : 101 - 107
  • [48] Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody
    Murakami, Shuji
    Shibaki, Ryota
    Matsumoto, Yuji
    Yoshida, Tatsuya
    Goto, Yasushi
    Kanda, Shintaro
    Horinouchi, Hidehito
    Fujiwara, Yutaka
    Yamamoto, Noboru
    Ohe, Yuichiro
    [J]. THORACIC CANCER, 2020, 11 (12) : 3585 - 3595
  • [49] Scoring of Programmed Death-Ligand 1 Immunohistochemistry on Cytology Cell Block Specimens in Non-Small Cell Lung Carcinoma: An Interobserver Agreement Study
    Hernandez, Andrea
    Brandler, Tamar C.
    Chen, Fei
    Zhou, Fang
    Xia, Yuhe
    Zhong, Judy
    Moreira, Andre L.
    Simms, Anthony
    Sun, Wei
    Wei, Xiao Jun
    Simsir, Aylin
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 154 (04) : 517 - 524
  • [50] Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade
    Tan, Daniel S. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (24) : 2735 - +